Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cyclacel Pharmaceuti (NQ: CYCC )

0.3170 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 25, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cyclacel Pharmaceuti

< Previous 1 2 3 Next >
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update
From Cyclacel
Via GlobeNewswire
Cyclacel Pharmaceuticals's Earnings Outlook
Via Benzinga
Recap: Cyclacel Pharmaceuticals Q1 Earnings
Via Benzinga
Oppenheimer Maintains Outperform Rating for Cyclacel Pharmaceuticals: Here's What You Need To Know
Via Benzinga
A Preview Of Cyclacel Pharmaceuticals's Earnings
Via Benzinga
Cyclacel Pharmaceuticals to Release Second Quarter 2023 Financial Results
From Cyclacel
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Why Cano Health Shares Are Trading Higher By 14%; Here Are 20 Stocks Moving Premarket
Gainers 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
It's time for another dive into the biggest pre-market stock movers as we check out all the latest news for Tuesday morning! 
Via InvestorPlace
Why Surgalign Holdings Shares Are Trading Lower By Around 75%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Airspan Networks Holdings Inc. (NYSE: MIMO) shares gained 79.5% to $0.2740. 
Via Benzinga
Cyclacel Pharmaceuticals Reports First Quarter Financial Results and Provides Business Update
From Cyclacel
Via GlobeNewswire
Cyclacel Pharmaceuticals to Release First Quarter 2023 Financial Results
From Cyclacel
Via GlobeNewswire
Cyclacel Pharmaceuticals Announces Receipt of $4.7 Million R&D Tax Credit
From Cyclacel
Via GlobeNewswire
Cyclacel Pharmaceuticals to Participate in March Investor Conferences
From Cyclacel
Via GlobeNewswire
Cyclacel Pharmaceuticals Reports Fourth Quarter And Full Year 2022 Financial Results And Provides Business Update
From Cyclacel
Via GlobeNewswire
Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2022 Financial Results
From Cyclacel
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Cyclacel Pharmaceuticals to Participate in the 2023 BIO CEO & Investor Conference
From Cyclacel
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Cyclacel Pharmaceuticals Reviews 2022 Achievements and Announces Key Business Objectives for 2023
From Cyclacel
Via GlobeNewswire
Cyclacel Pharmaceuticals to Present at Biotech Showcase and Participate in a Corporate Access Event During the J.P. Morgan Healthcare Conference in January 2023
From Cyclacel
Via GlobeNewswire
Cyclacel Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update
From Cyclacel
Via GlobeNewswire
Earnings Outlook For Cyclacel Pharmaceuticals
Cyclacel Pharmaceuticals (NASDAQ:CYCC) is set to give its latest quarterly earnings report on Wednesday, 2022-11-09. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
Cyclacel Pharmaceuticals to Release Third Quarter 2022 Financial Results
From Cyclacel
Via GlobeNewswire
Cyclacel Reports Preliminary Data From Its Phase 1/2 Clinical Trial of Oral Fadraciclib in Patients With Solid Tumors and Lymphoma at ENA 2022
Daily dosing of fadraciclib was well tolerated; single agent activity observed across multiple tumor types including 2 PRs in T-cell lymphoma patients 
From Cyclacel
Via GlobeNewswire
Cyclacel Hosting Research & Development Day
From Cyclacel
Via GlobeNewswire
Cyclacel Pharmaceuticals To Present Preliminary Data From The Phase 1/2 Clinical Trial Of Oral Fadraciclib At The 34th EORTC-NCI-AACR Symposium
- Preliminary Dose Escalation Data to be Presented on Novel CDK2/9 Inhibitor Fadraciclib in Patients with Solid Tumors and Lymphoma - 
From Cyclacel
Via GlobeNewswire
This Biotechnology Stock Tumbled 37%; Here Are 70 Biggest Movers From Yesterday
Gainers Bright Minds Biosciences Inc. (NASDAQ: DRUG) shares climbed 135.9% to close at $2.17 on Thursday. 
Via Benzinga
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.